Last Updated 23 October 2015
Biomarker- and histology-driven prescribing has become standard practice in the treatment of non-small-cell lung cancer (NSCLC). The treatment algorithms for NSCLC—including those for biomarker-defined patient subpopulations—continue to evolve, driven by the approval of novel agents, often with associated biomarkers. Several underserved areas of high unmet need offer significant commercial opportunity for innovative agents. This report provides insight on how treatment options for NSCLC patients are likely to change over the next decade. It also provides analysis of the current and future earnings potential of drugs already in the market and of drugs anticipated to be approved for this indication.